March 16, 2020 / 12:56 PM / 20 days ago

BRIEF-Genetx And Ultragenyx Announce First Patient Dosed In Phase 1/2 Clinical Trial Of GTX-102 In Patients With Angelman Syndrome

March 16 (Reuters) - Ultragenyx Pharmaceutical Inc:

* GENETX AND ULTRAGENYX ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL OF GTX-102 IN PATIENTS WITH ANGELMAN SYNDROME

* GENETX AND ULTRAGENYX ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL OF GTX-102 IN PATIENTS WITH ANGELMAN SYNDROME

* ULTRAGENYX PHARMACEUTICAL - GENETX BIOTHERAPEUTICS EXPECTS TO REPORT PRELIMINARY DATA FROM 1ST COHORTS IN STUDY IN EARLY 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below